Timing of Enoxaparin After Thrombolysis
Enoxaparin should be initiated 15 minutes after completing the thrombolytic infusion in patients under 75 years of age, or immediately after thrombolysis (without a bolus) in patients 75 years or older.
Evidence-Based Dosing Protocol
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines provide explicit timing and dosing for enoxaparin when used with fibrinolytic therapy 1:
For Patients <75 Years Old:
- 30 mg IV bolus immediately with thrombolysis
- Followed in 15 minutes by 1 mg/kg subcutaneous every 12 hours
- Maximum 100 mg for the first 2 doses
For Patients ≥75 Years Old:
- No IV bolus
- 0.75 mg/kg subcutaneous every 12 hours starting immediately after thrombolysis
- Maximum 75 mg for the first 2 doses
Renal Adjustment (All Ages):
- If CrCl <30 mL/min: 1 mg/kg subcutaneous every 24 hours (not every 12 hours)
Key Clinical Considerations
The critical distinction is that enoxaparin is NOT delayed after thrombolysis—it is initiated concurrently or within 15 minutes. This differs from the historical practice with unfractionated heparin, where timing was more variable.
The guideline evidence 1 demonstrates that this accelerated enoxaparin regimen:
- Provides predictable anticoagulant effect
- Easier administration than UFH
- Maintains therapeutic anticoagulation during the vulnerable post-thrombolysis period
Common Pitfalls to Avoid
- Do not wait hours after thrombolysis to start enoxaparin—the 15-minute interval is only for the subcutaneous dose after the IV bolus in younger patients
- Do not give the IV bolus to elderly patients (≥75 years)—this increases bleeding risk
- Do not forget renal dosing adjustments—failure to reduce frequency in renal impairment significantly increases bleeding complications
- Do not use standard VTE prophylaxis doses—the post-thrombolysis regimen requires full therapeutic dosing (1 mg/kg q12h, not 40 mg daily)
Supporting Evidence
Research data 2 confirms that enoxaparin combined with accelerated streptokinase regimens (with enoxaparin given as 40 mg IV followed by 1 mg/kg subcutaneous at 12-hour intervals) resulted in significantly higher coronary reperfusion rates (78.4%) and lower 30-day mortality (6.3%) compared to traditional regimens. The HART II trial 3 demonstrated that enoxaparin as an adjunct to thrombolysis showed trends toward higher recanalization rates and less reocclusion compared to UFH.
The timing is immediate to 15 minutes—not hours—after thrombolysis completion, with age-specific dosing protocols that must be strictly followed to balance efficacy and bleeding risk.